Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Riva Fineman is active.

Publication


Featured researches published by Riva Fineman.


American Journal of Infection Control | 2013

Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: A prospective controlled trial

Ilana Oren; Hannah Sprecher; Renato Finkelstein; Salim Hadad; Ami Neuberger; Keatam Hussein; Ayelet Raz-Pasteur; Noa Lavi; Elias Saad; Israel Henig; Netanel A. Horowitz; Irit Avivi; Noam Benyamini; Riva Fineman; Yishai Ofran; Nuhad Haddad; Jacob M. Rowe; Tsila Zuckerman

BACKGROUND Carbapenem-resistant Enterobacteriaceae (CRE) are emerging. In attempt to eradicate CRE colonization, we conducted a semirandomized, prospective, controlled trial using oral nonabsorbable antibiotics. METHODS Consecutive hospitalized CRE carriers were studied. Patients whose rectal isolates were gentamicin sensitive but colistin resistant were treated with gentamicin. Patients whose isolates were colistin sensitive but gentamicin resistant were treated with colistin. Patients whose isolates were sensitive to both drugs were randomized to 3 groups of oral antibiotic treatment: gentamicin, colistin, or both. Patients whose isolates were resistant to both drugs, and those who did not consent, were followed for spontaneous eradication. RESULTS One hundred fifty-two patients were included; 102 were followed for spontaneous eradication for a median duration of 140 days (controls), and 50 received 1 of the 3 drug regimens: gentamicin, 26; colistin, 16; both drugs, 8, followed for a median duration of 33 days. Eradication rates in the 3 treatment groups were 42%, 50%, and 37.5%, respectively, each significantly higher than the 7% spontaneous eradication rate in the control group (P < .001, P < .001, and P = .004, respectively) with no difference between the regimens. No significant adverse effects were observed. CONCLUSION Oral antibiotic treatment with nonabsorbable drugs to which CRE is susceptible appears to be an effective and safe for eradication of CRE colonization and, thereby, may reduce patient-to-patient transmission and incidence of clinical infection with this difficult-to-treat organism.


American Journal of Hematology | 2014

Richter's transformation to diffuse large B-cell lymphoma: A retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group

Tamar Tadmor; Lev Shvidel; Osnat Bairey; Neta Goldschmidt; Rosa Ruchlemer; Riva Fineman; Naomi Rahimi-Levene; Yair Herishanu; Mona Yuklea; Ariela Arad; Ariel Aviv; Aaron Polliack

Richters syndrome (RS) is the rare development of an aggressive lymphoid malignancy in a patient with pre‐existing chronic lymphocytic leukemia (CLL). Data on RS is sparse and mostly derived from case reports or small series of patients and only a few larger cohorts have been published. The purpose of this large retrospective study was to summarize our national experience with RS in CLL, examine possible risk factors, and analyze relevant demographic, laboratory and clinical parameters, including results of therapy and outcome. We first evaluated data obtained from 119 patients with RS diagnosed during 1971–2010 from 12 medical centers in Israel. The final cohort summarized consisted of 81 patients with RS who developed only diffuse large B‐cell lymphoma (DLBCL) after exclusion all cases with insufficient data and those who were not DLBCL. Median overall survival from time of diagnosis of RS was 8 months; after applying the Richter score, patients could be stratified into three prognostic groups, while all other clinical and laboratory parameters evaluated had no prognostic significance. Prior therapy for CLL had no impact on RS survival (P = 0.8) and patients with therapy “naïve” RS and those who had already received chemotherapy prior to developing RS, had the same survival. The addition of rituximab to chemotherapy for RS improved 2 years overall survival from 19% in the chemotherapy alone arm to 42% (P value of 0.001). Although prognosis of patients with RS remains dismal, this retrospective observation provides support for the use of chemo‐immunotherapy in DLBCL‐RS. Am. J. Hematol. 89:E218–E222, 2014.


Haematologica | 2015

Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience

Yair Herishanu; Neta Goldschmidt; Osnat Bairey; Rosa Ruchlemer; Riva Fineman; Naomi Rahimi-Levene; Lev Shvidel; Tamar Tadmor; Aviv Ariel; Andrea Braester; Mika Shapiro; Erel Joffe; Aaron Polliack

This study aimed to evaluate the efficacy and safety of the fludarabine-cyclophosphamide-rituximab regimen for young physically fit patients with chronic lymphocytic leukemia in the “real-life” setting. We specifically focused on the impact of dose reduction on patient outcomes. The patient cohort consisted of 128 patients with chronic lymphocytic leukemia (≤70 years) treated at 10 Israeli centers with front-line fludarabine-cyclophosphamide-rituximab. We defined reduced chemotherapy as two-thirds or less of the total indicated dose. Patients treated with rituximab were divided into two groups and compared: those who received full dosages of 375 mg/m2 or 500 mg/m2, and patients given less than six cycles with either dose. Overall and clinical complete response rates (92.8% and 70.4%), as well as toxicities and overall survival (median not reached at 6 years), were similar to other reported clinical trials, but progression-free survival was shorter (42.5 months). Almost 50% of patients had some dose reduction of chemotherapy, 21% receiving less than two-thirds of the indicated dose, while close to 30% did not complete six cycles of rituximab. Reduced doses of chemotherapy and rituximab were independently associated with shorter progression-free survival (hazard ratio 3.6, P<0.0001 for reduced chemotherapy; hazard ratio 2.5, P=0.003 for incomplete-treatment with rituximab). Achieving a complete response was associated with longer overall survival but was not linked to the given dose of chemoimmunotherapy. In younger physically fit patients, front-line fludarabine-cyclophosphamide-rituximab therapy in the “real-life” setting achieves long remissions (albeit shorter than in clinical trials) and prolonged overall survival. However, dose reductions are commonly administered and may impact outcome.


American Journal of Hematology | 2012

Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: risk stratified approach with a long-term follow-up.

Tsila Zuckerman; Tamar Katz; Nuhad Haddad; Riva Fineman; Eldad J. Dann; Irit Avivi; Yishai Ofran; Israel Gavish; Tal Faibish; Dvora Sahar; Eti Hertz; Edmond Sabo; Yair Reisner; Jacob M. Rowe

The use of allogeneic stem cell transplantation (SCT) for chronic myeloid leukemia (CML) was almost abandoned in recent years for very effective targeted therapy with tyrosine kinase inhibitors (TKIs). However, approximately one third of patients still need another treatment including SCT. 38 consecutive CML patients were treated (most in preimatinib era) with allogeneic SCT, using partial T cell depletion (TCD) and preemptive donor lymphocyte infusion (DLI), without post‐transplant graft‐versus‐host disease (GvHD) prophylaxis. Conditioning included busulfan, cyclophosphamide, antithymocytic globulin, and fludarabine followed by donor stem cell transfusion. With a median follow up of 90.5 months (1–134), 32 patients are alive. 97% engrafted. 5‐year leukemia free survival (LFS) and overall survival (OS) were 78.95% and 84.2%, respectively. All patients are in major molecular remission and 78% in complete molecular remission. Transplant‐related mortality (TRM) was 13%. Twenty‐four patients received DLI for residual disease. Acute GvHD, mostly Grades I‐II, occurred in 18% of patients post‐transplant and in 24% of patients receiving DLI. In conclusion, the risk‐adapted approach using only partial TCD and preemptive escalated dose of DLI precluded the need for immunosuppressive medications and reduced the risk of significant GvHD without compromising engraftment and long‐term disease control. Am. J. Hematol. 2012.


Transfusion | 2013

Alloimmune platelet transfusion refractoriness circumvented by allogeneic stem cell transplantation

Lilach Bonstein; Galia Stemer; Eldad J. Dann; Tsila Zuckerman; Riva Fineman; Nuhad Haddad

BACKGROUND: Administration of intensive chemotherapy used in the management of malignancies is accompanied with marrow suppression. Patients undergoing such treatments and especially those with acute leukemia need prolonged blood component support and are at risk for platelet (PLT) refractoriness. Irradiated and filtered blood, although effective, does not eliminate the risk for refractoriness and consequent fatal hemorrhage.


Hematological Oncology | 2018

Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival

Erel Joffe; N. Ariela Arad; Osnat Bairey; Riva Fineman; Rosa Ruchlemer; Naomi Rahimi-Levene; Lev Shvidel; Uri Greenbaum; Ariel Aviv; Tamar Tadmor; Neta Goldschmidt; Aaron Polliack; Yair Herishanu

Decreased absolute lymphocyte counts (ALCs) following frontline therapy for chronic lymphocytic leukemia may be associated with disease control, even in patients without evidence of minimal residual disease. We studied the prognostic significance of ALCs during the first year following treatment with fludarabine, cyclophosphamide, and rituximab (FCR).


European Journal of Haematology | 2018

Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials

Erel Joffe; Neta Goldschmidt; Osnat Bairey; Riva Fineman; Rosa Ruchlemer; Naomi Rahimi-Levene; Lev Shvidel; Uri Greenbaum; Ariel Aviv; Tamar Tadmor; Andrea Braester; Ariela Arad; Aaron Polliack; Yair Herishanu

To evaluate disease characteristics and long‐term outcomes in patients requiring second‐line treatment following fludarabine, cyclophosphamide, and rituximab (FCR), for relapsed/refractory disease (R/R), or following discontinuation due to toxicities.


Journal of Clinical Oncology | 2002

Tumor Lysis Syndrome After STI571 in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Eldad J. Dann; Riva Fineman; Jacob M. Rowe


Anticancer Research | 2014

Hodgkin's Variant of Richter Transformation in Chronic Lymphocytic Leukemia; A Retrospective Study from the Israeli CLL Study Group

Tamar Tadmor; Lev Shvidel; Neta Goldschmidt; Rosa Ruchlemer; Riva Fineman; Osnat Bairey; Naomi Rahimi-Levene; Yair Herishanu; Mona Yuklea; Ariela Arad; Ariel Aviv; Aaron Polliack


Biology of Blood and Marrow Transplantation | 2016

Adult Nephrotic Syndrome after Hematopoietic Stem Cell Transplantation: Renal Pathology is the Best Predictor of Response to Therapy

Ofrat Beyar-Katz; Etty Kruzel Davila; Tsila Zuckerman; Riva Fineman; Nuhad Haddad; Doaa Okasha; Israel Henig; Ronit Leiba; Jacob M. Rowe; Yishai Ofran

Collaboration


Dive into the Riva Fineman's collaboration.

Top Co-Authors

Avatar

Jacob M. Rowe

Shaare Zedek Medical Center

View shared research outputs
Top Co-Authors

Avatar

Nuhad Haddad

Technion – Israel Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Tsila Zuckerman

Technion – Israel Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Aaron Polliack

Hebrew University of Jerusalem

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rosa Ruchlemer

Shaare Zedek Medical Center

View shared research outputs
Top Co-Authors

Avatar

Tamar Tadmor

Rappaport Faculty of Medicine

View shared research outputs
Top Co-Authors

Avatar

Yair Herishanu

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge